INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,734,779 | -25.1% | 935,587 | -8.9% | 0.01% | -16.7% |
| Q2 2023 | $65,056,616 | +68.4% | 1,027,425 | +44.0% | 0.01% | +50.0% |
| Q1 2023 | $38,642,794 | -24.0% | 713,625 | -25.7% | 0.00% | -33.3% |
| Q4 2022 | $50,814,736 | +25.5% | 960,218 | +10.3% | 0.01% | 0.0% |
| Q3 2022 | $40,503,000 | -8.7% | 870,460 | +12.0% | 0.01% | 0.0% |
| Q2 2022 | $44,380,000 | +10.9% | 777,537 | +18.9% | 0.01% | +20.0% |
| Q1 2022 | $40,016,000 | +10.0% | 653,984 | -5.9% | 0.01% | +25.0% |
| Q4 2021 | $36,371,000 | +32.2% | 694,898 | -5.8% | 0.00% | 0.0% |
| Q3 2021 | $27,515,000 | +1.6% | 738,020 | +11.3% | 0.00% | 0.0% |
| Q2 2021 | $27,074,000 | +82.2% | 663,263 | +51.4% | 0.00% | +100.0% |
| Q1 2021 | $14,863,000 | -2.7% | 438,061 | -8.8% | 0.00% | 0.0% |
| Q4 2020 | $15,275,000 | +17.3% | 480,343 | -5.3% | 0.00% | -33.3% |
| Q3 2020 | $13,021,000 | -0.2% | 507,421 | -0.2% | 0.00% | 0.0% |
| Q2 2020 | $13,046,000 | +56.8% | 508,191 | -6.1% | 0.00% | +50.0% |
| Q1 2020 | $8,320,000 | -73.3% | 541,290 | -40.3% | 0.00% | -71.4% |
| Q4 2019 | $31,106,000 | +421.7% | 906,611 | +13.6% | 0.01% | +250.0% |
| Q3 2019 | $5,962,000 | -0.5% | 798,051 | +72.9% | 0.00% | 0.0% |
| Q2 2019 | $5,993,000 | +7.6% | 461,669 | +0.9% | 0.00% | 0.0% |
| Q1 2019 | $5,569,000 | -4.3% | 457,328 | -10.5% | 0.00% | 0.0% |
| Q4 2018 | $5,820,000 | -53.7% | 510,998 | -11.7% | 0.00% | -33.3% |
| Q3 2018 | $12,560,000 | +22.1% | 578,818 | -0.6% | 0.00% | 0.0% |
| Q2 2018 | $10,286,000 | -17.0% | 582,111 | -1.2% | 0.00% | 0.0% |
| Q1 2018 | $12,397,000 | +61.0% | 588,965 | +10.8% | 0.00% | +50.0% |
| Q4 2017 | $7,698,000 | -16.4% | 531,717 | -8.9% | 0.00% | -33.3% |
| Q3 2017 | $9,210,000 | +58.8% | 583,646 | +25.0% | 0.00% | +50.0% |
| Q2 2017 | $5,799,000 | -58.7% | 466,921 | -45.9% | 0.00% | 0.0% |
| Q1 2017 | $14,034,000 | -5.4% | 863,646 | -12.2% | 0.00% | 0.0% |
| Q4 2016 | $14,842,000 | +118.5% | 983,688 | +120.6% | 0.00% | 0.0% |
| Q3 2016 | $6,793,000 | -57.9% | 445,832 | +7.4% | 0.00% | -66.7% |
| Q2 2016 | $16,121,000 | +43.0% | 415,267 | +2.4% | 0.01% | +50.0% |
| Q1 2016 | $11,271,000 | -41.2% | 405,482 | +13.8% | 0.00% | -42.9% |
| Q4 2015 | $19,160,000 | -16.5% | 356,193 | -37.8% | 0.01% | -12.5% |
| Q3 2015 | $22,937,000 | +89.8% | 572,855 | +51.5% | 0.01% | +100.0% |
| Q2 2015 | $12,083,000 | +51.5% | 378,210 | +13.2% | 0.00% | +33.3% |
| Q1 2015 | $7,977,000 | +75.3% | 334,008 | +29.5% | 0.00% | +50.0% |
| Q4 2014 | $4,551,000 | +45.6% | 257,850 | +13.1% | 0.00% | +100.0% |
| Q3 2014 | $3,126,000 | -23.3% | 228,001 | -5.6% | 0.00% | -50.0% |
| Q2 2014 | $4,074,000 | +82.7% | 241,561 | +96.9% | 0.00% | +100.0% |
| Q1 2014 | $2,230,000 | – | 122,688 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |